Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults

Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRNA-1944 (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Moderna Therapeutics
  • Most Recent Events

    • 12 Jan 2020 According to a Moderna Therapeutics media release, dosing of the cohort at 0.6 mg/kg with steroid premedication has begun.Dosing of an additional cohort with two doses of 0.3 mg/kg (without steroid premedication) given one week apart is expected.
    • 06 Nov 2019 According to the Moderna Therapeutics media release, the company has presented data, in Oct 2019, at the Annual Meeting of the Oligonucleotide Therapeutics Society.
    • 06 Nov 2019 According to the Moderna Therapeutics media release, dosing of two additional cohorts are planned to begin in the near term.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top